Glaxo Ordered to End Avandia Drug Trial Enrollment

more+
less-

The Food and Drug Administration has ordered GlaxoSmithKline to stop enrolling people in a controversial clinical trial comparing diabetes drugs, and to notify more than 1,300 people already undergoing tests that they may be at greater risk for heart attacks because they have taken Avandia.

Please see full article below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Published In: Administrative Agency Updates, Health Updates, Personal Injury Updates, Products Liability Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Robert Kraft, Kraft & Associates | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »